G1 and G2 cell-cycle arrest following microtubule depolymerization in human breast cancer cells

April L. Blajeski,1 Vy A. Phan,2 Timothy J. Kottke,3 and Scott H. Kaufmann1,2,3

1Department of Molecular Pharmacology and Experimental Therapeutics, 2Tumor Biology Program, Mayo Graduate School, and 3Division of Oncology Research, Mayo Clinic, Rochester, Minnesota, USA

Microtubule-depolymerizing agents are widely used to synchronize cells, screen for mitotic checkpoint defects, and treat cancer. The present study evaluated the effects of these agents on normal and malignant human breast cell lines. After treatment with 1 μM nocodazole, seven of ten breast cancer lines (type A cells) arrested in mitosis, whereas the other three (type B cells) did not. Similar effects were observed with 100 nM vincristine or colchicine. Among five normal mammary epithelial isolates, four exhibited type A behavior and one exhibited type B behavior. Further experiments revealed that the type B cells exhibited a biphasic dose-response curve, with mitotic arrest at low drug concentrations (100 nM nocodazole or 6 nM vincristine) that failed to depolymerize microtubules and a p53-independent p21\textsuperscript{Waf1/Cip1}-associated G1 and G2 arrest at higher concentrations (1 μM nocodazole or 100 nM vincristine) that depolymerized microtubules. Collectively, these observations provide evidence for coupling of premitotic cell-cycle progression to microtubule integrity in some breast cancer cell lines (representing a possible “microtubule integrity checkpoint”) and suggest a potential explanation for the recently reported failure of some cancer cell lines to undergo nocodazole-induced mitotic arrest despite intact mitotic checkpoint proteins.


Introduction

Nocodazole, vincristine, and colchicine are structurally diverse agents that disrupt microtubule function by binding to various sites on β-tubulin and suppressing microtubule dynamics or inducing microtubule depolymerization (1–3). These actions are useful in cell synchronization studies, where brief exposures to nocodazole are routinely used to reversibly arrest cells in mitosis (4, 5). In addition, vinca alkaloids are used to treat several neoplasms (3), including breast cancer.

Microtubule-disrupting agents are thought to arrest cells in mitosis by triggering the mitotic checkpoint, a series of biochemical reactions that ensure proper attachment of chromosomes to the mitotic spindle before cells enter anaphase (reviewed in refs. 6–9). When microtubules fail to attach to one or more kinetochores as a result of drug treatment, components of the checkpoint continue to generate signals that inhibit the metaphase/anaphase transition.

Like most cell-cycle checkpoints, the mitotic checkpoint can adapt. After prolonged treatment with microtubule-disrupting agents, cells exit mitosis without undergoing cytokinesis. These cells then enter an abnormal, tetraploid G1-like phase (10–13) in which they are susceptible to activation of a “microtubule-sensitive” G1 checkpoint (11, 14, 15) that results in p53-mediated upregulation of the cyclin-dependent kinase (Cdk) inhibitor p21\textsuperscript{Waf1/Cip1} (p21) (16–20). p21 in turn inhibits the activity of Cdk2- and Cdk4-cyclin complexes, thereby arresting the cells in a tetraploid G1 state (reviewed in ref. 21).

In addition to arresting cells in G1, p21 can inhibit Cdc2-cyclin B complexes (21) and proliferating cell nuclear antigen (22–24), preventing interaction of the latter with other components of the DNA polymerase complex. One or both of these actions can contribute to a G2 arrest following ectopic p21 expression or DNA damage (25, 26). Previous studies have not, however, implicated p21 in premiotic G1 or G2 arrests after microtubule disruption.

In the present work, we examined the effects of microtubule-depolymerizing agents on a series of human breast cancer cell lines and normal human mammary epithelial cells (HMECs), using conditions previously reported to identify cancer cell lines harboring mitotic checkpoint defects (27–30). Our results indicate that HMEC and breast cancer cell lines can be divided into two groups, those that respond with the expected mitotic arrest and those that do not. To our surprise, these differences reflected a previously undescribed p21-associated premiotic G1 and G2 arrest that

Received for publication May 15, 2001, and accepted in revised form May 23, 2002.

Address correspondence to: Scott H. Kaufmann, Guggenheim 1301, Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905, USA. Phone: (507) 284-8950; Fax: (507) 284-3906; E-mail: kaufmann.scott@mayo.edu.

Conflict of interest: No conflict of interest has been declared.

Nonstandard abbreviations used: cyclin-dependent kinase (Cdk); Cdk inhibitor p21\textsuperscript{Waf1/Cip1} (p21); human mammary epithelial cells (HMECs); propidium iodide (PI); bromodeoxyuridine (BrdU).
prevented some of the cell lines from ever reaching mitosis. These observations suggest that the effects of a whole class of widely used pharmacological agents are more complicated than previously suspected.

**Methods**

**Materials.** Nocodazole, vincristine, and colchicine were purchased from Sigma-Aldrich (St. Louis, Missouri, USA). Taq polymerase and reverse transcriptase were obtained from Roche Molecular Biochemicals (Indianapolis, Indiana, USA) and Promega Corp. (Madison, Wisconsin, USA), respectively. Murine monoclonal antibodies were purchased as follows: anti-cyclin B from Oncogene Research Products (Cambridge, Massachusetts, USA), anti-GADD45 from Santa Cruz Biotechnology Inc. (Santa Cruz, California, USA), anti-α-tubulin from Amersham Pharmacia Biotech (Piscataway, New Jersey, USA), and anti-p53 (clone 1801) and anti-p21 (Ab-11) from NeoMarkers (Fremont, California, USA) and R. Abraham (Burnham Institute, La Jolla, California, USA) provided antisera to CENP-F and cyclin E, respectively. All others were obtained as recently described (31).

**Cell culture and determination of mitotic index.** Breast cancer lines from American Type Culture Collection (Manassas, Virginia, USA) and low-passage HMECs from Clonetics Corp. (Walkersville, Maryland, USA) were cultured in the media designated by the suppliers. Treatment with drugs (prepared as 1,000-fold concentrated stocks in dimethyl sulfoxide) as described in the figure legends, adherent and nonadherent cells were combined, sedimented at 200 g, and incubated in 75 mM KCl for 15 minutes at 37°C. Cells were then fixed in 3.7% formaldehyde, washed with calcium- and magnesium-free PBS (32), sedimented onto glass slides at 90 g, stained with 1 μg/ml Hoechst 33258, and examined by fluorescence microscopy. At least 300 nuclei per sample were scored as interphase, mitotic, or apoptotic.

**Cell-cycle analysis.** After sedimentation at 200 g for 10 minutes, cells were washed with ice-cold PBS, fixed in 50% (vol/vol) ethanol, treated with 1 mg/ml RNase A, stained with 100 μg/ml propidium iodide (PI), and subjected to flow cytometry (33). DNA histograms were analyzed using ModFit software (Verity Software House Inc., Topsham, Maine, USA). For cell sorting experiments, cells containing 2N or 4N DNA were separated based on PI fluorescence using a FACSVantage SE (Becton, Dickinson and Co., San Jose, California, USA) and prepared for SDS-PAGE as described below. For bromodeoxyuridine (BrDU) incorporation studies, cells were pulsed with 20 μM BrDU for 20 minutes, washed, and treated with 1 μM nocodazole or 100 nM vincristine for 18 or 24 hours. After treatment, cells were trypsinized, centrifuged at 200 g, washed in ice-cold PBS, fixed in 66% (vol/vol) ethanol at −20°C, labeled with anti-BrDU antibody followed by PI, and subjected to flow cytometry as recently described (31).

**Immunoblotting.** Cells were washed twice with PBS and lysed in 6 M guanidine hydrochloride containing 250 mM Tris-HCl (pH 8.5 at 21°C), 10 mM EDTA, 150 mM β-mercaptoethanol, and 1 mM PMSF. After sonication and alklylation, samples were dialyzed into SDS and lyophilized (33). Aliquots containing 50 μg of total cellular protein were subjected to SDS-PAGE on 12% (wt/vol) polyacrylamide gels, transferred to nitrocellulose, and probed with antibodies as described (33).

**Indirect immunofluorescence.** Cells growing on coverslips were treated with nocodazole or vincristine for 8–24 hours as indicated in the figure legends. For CENP-F staining, coverslips were fixed in cold methanol for 20 minutes, air dried, and immediately washed once in PBS. For tubulin or cyclin B staining, samples were fixed in 3.7% formaldehyde and permeabilized in 0.1% Triton X-100. For all stains, coverslips were incubated overnight at 4°C in blocking buffer consisting of 10% (wt/vol) powdered milk, 150 mM NaCl, 10 mM Tris-HCl (pH 7.4 at 21°C), 100 μg/ml penicillin, 100 μg/ml streptomycin, and 1 mM sodium azide; treated with primary antibodies for 1 hour in a humidified chamber at 37°C; washed three times in PBS; incubated with FITC-conjugated secondary antibodies for 1 hour at 37°C; washed in PBS; and counterstained with 0.5 μg/ml Hoechst 33342. Samples were photographed using MetaMorph computer software (Universal Imaging Corp., West Chester, Pennsylvania, USA) and a Hamamatsu C4742 digital camera (Hamamatsu Corp., Bridgewater, New Jersey, USA) mounted on a Zeiss IM35 microscope (Carl Zeiss Inc., Thornwood, New York, USA).

**RT-PCR.** After 2-μg aliquots of poly(A) RNA were reverse transcribed, 1/25 of the resulting cDNA was used for each amplification. Following initiation under hot start conditions, PCR reactions were continued for 28 cycles on a PE 480 thermal cycler (PE Biosystems, Foster City, California, USA) using 92°C for denaturation, 55°C for annealing, and 72°C for extension (1 min/step). The following primers were used: p21 forward, 5'-CTGGCCGGAAGTCAGTTCC-3' and p21 reverse, 5'-CTGTGGGGGAGTAGGGG-3'; β-actin forward, 5'-GTGGGGCCGCCTTCGACCA-3' and β-actin reverse, 5'-TCCCTTAATGTCCAGCAGATTTCC-3'. Amplified products were separated on a 1% agarose gel, visualized under UV light, and sequenced to confirm their identity.

**Results**

Two types of cellular responses following treatment with 1 μM nocodazole or 100 nM vincristine. In experiments designed to search for mitotic checkpoint dysfunction, the ability of 1 μM nocodazole to produce mitotic arrest was examined in ten breast cancer cell lines. Seven of these cell lines (MCF-7, MDA-MB-231, MDA-MB-436, MDA-MB-453, HS0578T, SKBr3, and ZR-75-10) exhibited the expected mitotic arrest, with an increase in mitotic index of 10 fold or more, and mean mitotic indices in excess of 20% after nocodazole exposure in each line. The mitotic index of MCF-7 cells, for example, increased from 2.2% ± 1.4% in diluent to 39% ± 11% (mean ± SD of 11 separate experiments) after 16–24
hours in nocodazole (Figure 1, a and b). In contrast, three cell lines (MDA-MB-468, BT20, and T47D) displayed a much less prominent mitotic arrest, with two-to fourfold increases in mitotic index, and mean mitotic indices below 10% after nocodazole treatment. The mitotic index of MDA-MB-468 cells, for example, increased from 2.4% ± 1.4% to 8.1% ± 3.5% (n = 13) after 16–24 hours in nocodazole. Results obtained with two lines that displayed prominent mitotic arrest (which we will designate “type A” cells) and two that did not (“type B” cells) are shown in Figure 1b. A similar dichotomy was observed when these four cell lines were treated with 100 nM vincristine (Figure 1c) or 100 nM colchicine (data not shown).

Cell-cycle effects of paclitaxel. One potential explanation for failure of some lines to arrest in mitosis would be the presence of mitotic checkpoint dysfunction. If this were the case, these cell lines should also fail to arrest in mitosis when treated with paclitaxel, an agent that activates the mitotic checkpoint (34, 35) by suppressing microtubule dynamics at low concentrations and causing tubulin hyperpolymerization at high concentrations (36). Contrary to this prediction, all the cell lines displayed a robust mitotic arrest during paclitaxel treatment (Figure 1d and data not shown).

In further experiments, basal levels of the mitotic checkpoint proteins BUB1, BUBR1, BUB3, MAD2, and p55Cdc20 were examined in all ten cell lines. Aside from the previously reported (28) low levels of MAD2 in T47D cells, there were no obvious defects in these mitotic checkpoint components that could explain the behavior of the type B cells (data not shown).

Another potential explanation for the failure to arrest in mitosis would be the occurrence of inefficient drug uptake or excessive drug efflux. As will be illustrated below (see Figure 6c), α-tubulin staining demonstrated microtubule depolymerization in type B cells treated with nocodazole, vincristine, or colchicine (data not shown), suggesting that the drugs were present and active within these cells.

Response of HMECs to microtubule-directed agents. Additional experiments examined the mitotic indices of normal HMECs after treatment with nocodazole, vincristine, or paclitaxel. For the HMEC isolate depicted in Figure 1e, each agent arrested a similar number of cells in mitosis. Similar results were observed with three additional independent HMEC isolates. In contrast, one isolate showed type B behavior that is characterized in greater detail below (see Figure 5c and accompanying text).

Nocodazole induces G1 and G2 arrest in MDA-MB-468 cells. Further experiments were performed to investigate the mechanistic basis for behavior of type B cells. Consistent with the mitotic arrest seen in Figure 1d, flow cytometry indicated that paclitaxel caused the MDA-MB-468 cells to accumulate in a tetraploid (4N) state (Figure 2b). In contrast, 1 µM nocodazole or 100 nM vincristine caused accumulation of cells in both 2N and 4N states, while the percentage of cells in S phase decreased (Figure 2, c and d). In additional experiments, similar results were observed in BT20 and T47D cells. These results raised the possibility that nocodazole or vincristine might cause these cells to arrest in both G1 and G2 before they ever reach mitosis.

To confirm that the 2N cells present after nocodazole and vincristine treatment resulted from G1 arrest rather than progression of 4N cells through mitosis and cytokinesis, we pulsed MDA-MB-468 cells with 20 µM BrdU and determined whether the labeled S phase cells arrested in G2 or continued through mitosis to the next G1 phase. When diluent was added after BrdU labeling, about 68% of the labeled cells were found to be in G1 18 hours after treatment (Figure 2b). In contrast, 1 µM nocodazole or 100 nM vincristine caused accumulation of cells in both 2N and 4N states, while the percentage of cells in S phase decreased (Figure 2, c and d). In additional experiments, similar results were observed in BT20 and T47D cells. These results raised the possibility that nocodazole or vincristine might cause these cells to arrest in both G1 and G2 before they ever reach mitosis.

Figure 1
Two types of behavior following treatment of human breast cancer cell lines with microtubule-depolymerizing agents. (a) After a 24-hour treatment with 1 µM nocodazole, adherent and nonadherent MDA-MB-468 or MCF-7 cells were combined, stained with Hoechst 33258, and examined by fluorescence microscopy. Note that MDA-MB-468 cells remained in interphase, whereas many MCF-7 cells arrested in mitosis. (b-d) Breast cancer cells (filled triangles, MCF-7; filled circles, HS0578T; open triangles, BT20; open circles, MDA-MB-468) were treated with 1 µM nocodazole (b), 100 nM vincristine (c), or 100 nM paclitaxel (d) for various periods of time. Alternatively, HMECs (e) were treated with these agents for 14 hours, a length of time chosen because this isolate doubled every 16 hours. After adherent and nonadherent cells were combined, the morphology of 300 or more nuclei in each sample was scored by fluorescence microscopy. In b-d, representative individual experiments are shown and the degree of variation is indicated in the text. In e, the mean and range of two experiments are shown. Ctrl, control; Pacl, paclitaxel; Noco, nocodazole; Vin, vincristine.
MDA-MB-468 cells arrest in G1 and G2 following nocodazole and vincristine treatment. Cells treated with diluent (a), 100 nM paclitaxel (b), 1 µM nocodazole (c), or 100 nM vincristine (d) for 24 hours were stained with PI and subjected to flow cytometry. Numbers in each panel show mean ± SD of distributions inferred from PI staining of three to six separate experiments using ModFit.

Figure 2

Table 1

<table>
<thead>
<tr>
<th></th>
<th>18 h</th>
<th>24 h</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>68.1 ± 12.0</td>
<td>75.5 ± 18.7</td>
</tr>
<tr>
<td>Nocodazole</td>
<td>4.9 ± 2.9</td>
<td>6.5 ± 0.8</td>
</tr>
<tr>
<td>Vincristine</td>
<td>5.2 ± 2.7</td>
<td>6.6 ± 4.3</td>
</tr>
</tbody>
</table>

MDA-MB-468 cells were pulsed with 20 µM BrdU for 20 minutes, washed, and incubated in the absence (control) or presence of 1 µM nocodazole or 100 nM vincristine for various periods of time. The cell-cycle distribution of labeled, adherent cells was examined as described in Methods. Results are mean ± SD of three independent experiments.
centrations, e.g., 150–300 nM nocodazole (Figure 5a) or 6–12 nM vincristine (data not shown), even though these cells did not arrest at higher concentrations (Figure 1, a–c). Similar results were observed with T47D cells (Figure 5b), BT20 cells (not shown), and an HMEC isolate that exhibited type B behavior (Figure 5c). This mitotic arrest at low concentrations suggests that intrinsic mitotic checkpoint defects or altered drug accumulation are unlikely to account for the behavior of type B cells at higher drug concentrations. In contrast, numerous type A cells, including MCF-7, MDA-MB-231, MDA-MB-453, ZR-75-10, and SKBr3 cells, exhibited a robust mitotic arrest when treated with nocodazole concentrations ranging up to 30 µM (Figure 5d and data not shown). These observations rule out the possibility that type B behavior can be elicited in type A cells by merely increasing the drug concentration. Instead, it appears that breast cancer cells will arrest in mitosis following exposure to low or high doses of nocodazole unless other events (e.g., G1 and G2 arrest) intervene and prevent the cells from reaching M phase.

To determine whether similar dose-dependent effects might be observed with paclitaxel, mitotic indices were determined after MDA-MB-468 cells were treated for 22–24 hours with paclitaxel at concentrations ranging from 100 nM to 10 µM. Results of this analysis (Figure 5e) failed to provide evidence for diminished mitotic arrest at high drug concentrations. Instead, the premiotic arrest observed in type B cells appeared to be limited to microtubule-destabilizing agents.

To further evaluate the potential role of p21 in the nocodazole-induced G1 and G2 arrests, p21 levels were examined in MDA-MB-468 cells treated with varying concentrations of nocodazole. p21 consistently increased in MDA-MB-468 cells only at nocodazole concentrations (300–1,000 nM) that inhibited mitotic arrest (Figure 5f). When multiple cell lines were examined after treatment with 1 µM nocodazole, p21 was also elevated in BT20 and T47D cells (Figure 5g), which exhibited type B behavior, but not in MCF-7, MDA-MB-231, MDA-MB-453, or SKBr3 cells (Figure 5h and data not shown), which exhibited type A behavior.

**Relationship between cell-cycle arrest and microtubule depolymerization.** Because low doses of nocodazole and vincristine reportedly stabilize microtubule dynamics without any alteration in microtubule mass (43), after treatment with 1 µM nocodazole, however, microtubules in the two cell lines exhibited different behaviors: intact microtubules could still be observed in MCF-7 cells (Figure 6f) but not in MDA-MB-468 cells (Figure 6e). Experiments in other cell lines, however, ruled out the possibility that these different microtubule behaviors correlate with cell-cycle response. Although other type B cells (T47D, BT20, and the HMEC isolate shown in Figure 5c) also displayed extensive microtubule depolymerization at 1-3
while PARP served as a loading control. (Page and probed for p21. p53, which is mutated in these cells (41), was subjected to SDS-PAGE followed by immunoblotting. Cyclin B and GADD45 (GD45), or p53 (as a loading control). (Poly(A)+ RNA from cells treated with 1 µM nocodazole for various lengths of time was analyzed by RT-PCR using primers specific for p21. β-actin served as a control. (Cells were treated with 1 µM nocodazole for various lengths of time before SDS-PAGE and immunoblotting for p21, GADD45 (GD45), or p53 (as a loading control). (Cells were treated with 1 µM nocodazole for 24 hours, fixed in 50% ethanol, stained with PI, and sorted into 2N and 4N populations by flow cytometry (gates set as shown). Protein (50 µg) from unsorted (total) or sorted (2N or 4N) cell populations was subjected to SDS-PAGE followed by immunoblotting. Cyclin B and cyclin E served as markers of the G2 and G1 populations, respectively, while PARP served as a loading control.

Figure 4
Increased p21 expression after treatment of MDA-MB-468 cells with microtubule-depolymerizing agents. (a) Cells were treated with 1 µM nocodazole, 100 nM paclitaxel, 100 nM vincristine, or 100 nM colchicine for 24 hours. Whole-cell lysates were subjected to SDS-PAGE and probed for p21, p53, which is mutated in these cells (41), served as a loading control. (b) Poly(A)+ RNA from cells treated with 1 µM nocodazole for various periods of time was analyzed by RT-PCR using primers specific for p21. β-actin served as a control. (c) Cells were treated with 1 µM nocodazole for various lengths of time before SDS-PAGE and immunoblotting for p21, GADD45 (GD45), or p53 (as a loading control). (d and e) Cells were treated with 1 µM nocodazole for 24 hours, fixed in 50% ethanol, stained with PI, and sorted into 2N and 4N populations by flow cytometry (gates set as shown). Protein (50 µg) from unsorted (total) or sorted (2N or 4N) cell populations was subjected to SDS-PAGE followed by immunoblotting. Cyclin B and cyclin E served as markers of the G2 and G1 populations, respectively, while PARP served as a loading control.

µM nocodazole (similar to Figure 6c), so did MDA-MB-453, MDA-MB-431, and an HMEC isolate that displayed type A behavior. Thus, G1 and G2 arrests occurred in type B cells at drug concentrations that depolymerized microtubules; but microtubule depolymerization did not guarantee type B behavior.

Discussion
In the present study, morphological analysis indicated that ten breast cancer cell lines could be divided into two groups: those that display a prominent mitotic arrest after treatment with 1 µM nocodazole, 100 nM vincristine, or 100 nM colchicine (type A cells), and those that do not (type B cells). Nontransformed HMECs exhibited a similar dichotomy. Further experiments demonstrated that type B cells arrest in mitosis at low drug concentrations but undergo p21-associated G1 and G2 arrests at higher drug concentrations. These results have potentially important implications for current understanding of the actions of spindle poisons.

Because type A cells exhibited the expected response to microtubule-depolymerizing agents, much of the present analysis focused on type B cells. Several observations suggested that these cells have intact mitotic checkpoints. First, type B cells arrested in mitosis after treatment with paclitaxel (Figure 1d, Figure 5c, and data not shown), another agent that activates the mitotic checkpoint (35, 44). Second, type B cells arrested in mitosis at lower concentrations of nocodazole, vincristine, or colchicine (Figure 5, a and b, and data not shown), demonstrating that the machinery responsible for mitotic arrest was functionally intact. Third, BrdU labeling (Table 1) and cyclin analysis (Figure 3e and Figure 4e) indicated that these cells failed to reenter G1, a cell-cycle phase they would be expected to enter if the mitotic checkpoint malfunctioned.

Defects in the checkpoint protein Chfr also fail to account for the behavior of type B cells. Upon treatment with 1.5 µM nocodazole, 1.5 µM colcemid, or 5 µM paclitaxel during G2, tumor cell lines lacking Chfr rapidly accumulate in mitosis, whereas cells expressing Chfr exhibit a 6-hour delay before entering mitosis (45). The failure of type B cells to accumulate in mitosis when followed for as long as 72 hours after treatment with 1 µM nocodazole or 100 nM vincristine (Figure 1, b and c, and data not shown) clearly distinguished type B cells from Chfr-deficient cells as well.

Further investigation revealed that MDA-MB-468 cells, a prototypic type B cell line, arrested in both G1 and G2 after treatment with 1 µM nocodazole or 100 nM vincristine. The presence of a G1 arrest was indicated by the persistence of cells with 2N DNA content and high cyclin E levels (Figure 2, c and d, and Figure 4, d and e) despite the failure of 4N cells to undergo cytokinesis (Table 1). The presence of a G2 arrest was indicated by the accumulation of 4N cells (Figure 2, c and d) with interphase morphology (Figure 1a and Figure 3), high levels of cytoplasmic cyclin B (Figure 3, e and f, and Figure 4e), and focal staining for CENP-F (Figure 3, b, c, and g). Although microtubule-disrupting agents have been observed to induce accumulation in a tetraploid G1-like state following mitotic delay and abnormal mitotic exit (11, 14–20), to our knowledge this is the first report of premitotic G1 and G2 arrest induced by these agents.

These premitotic G1 and G2 arrests are associated with increased expression of p21 (Figure 4), a Cdk inhibitor that plays critical roles in G1 and G2 arrests after DNA damage (26, 46). Several observations raised the possibility that p21 might contribute to the behavior of the type B cells. First, elevated p21 levels were observed in both G1 and G2 cell populations (Figure
Second, p21 levels increased after treatment with nocodazole, vincristine, or colchicine, but not paclitaxel, which failed to induce G1 and G2 arrests (Figure 1d and Figure 4a). Third, p21 levels were significantly elevated (four- to eightfold) only after treatment with nocodazole concentrations that caused the G1 and G2 arrests in type B cells (Figure 5, a and f). Finally, p21 levels increased in additional type B cells (Figure 5g) but not type A cells (Figure 5h). Although these observations establish a correlation between p21 elevation and the observed G1 and G2 arrests, more definitive evidence that p21 participates in type B behavior will require the examination of p21–/– cells. Unfortunately, parental cells corresponding to both currently available p21–/– cell lines (mouse fibroblasts and HCT116 colon cancer cells) exhibit type A behavior in response to nocodazole (refs. 27, 47, and data not shown), making these models unsuitable for assessing the role of p21 in the type B response.

The events leading from microtubule disturbance to p21 upregulation in type B cells require further study. The failure of other DNA damage–responsive polypeptides such as GADD45 to accumulate (Figure 4a) distinguishes nocodazole-induced p21 upregulation from a DNA damage response. Moreover, the accumulation of p21 in MDA-MB-468 cells, which contain mutant...
p53 (41), suggests that nocodazole-induced p21 upregulation does not depend on p53 function.

Consistent with this latter conclusion, no relationship between p53 status and nocodazole-induced cell-cycle effects was observed. In particular, cells with p53 mutations exhibited both type A (MDA-MB-231, SKBr3, Hs5078T) and type B (MDA-MB-468, T47D) behavior. Likewise, as described above, differences in microtubule stability did not track with type A versus type B behavior. Instead, the observation that different HMEC isolates also exhibit this dichotomous behavior (Figure 1e and Figure 5c) raised the possibility that allelic polymorphism in a currently unidentified gene determines the cell-cycle response to microtubule disruption.

The results presented above have potentially important implications for current efforts to study mitotic checkpoint function in cancer cell lines. Recent studies have demonstrated that approximately 50% of colon cancer cell lines fail to arrest upon exposure to 0.7 µM nocodazole. Although BUB1 mutations were demonstrated in two of these lines, extensive analysis failed to identify additional mutations in mitotic checkpoint genes in a variety of cancer cell lines (48–50). Our results indicate that the use of high-dose nocodazole to screen for mitotic checkpoint defects in breast cancer lines results in false positives because a number of lines arrest in G1 and G2 before reaching mitosis. Whether similar limitations apply to other cell types remains to be determined.

In summary, the present observations lead to a number of unexpected conclusions. First, microtubule-depolymerizing agents can cause simultaneous G1 and G2 arrests before some cells ever reach mitosis. Second, this type B phenotype correlates with p53-independent induction of p21. Third, type B behavior occurs in some HMEC isolates as well as breast cancer cell lines, raising the possibility that it reflects normal phenotypic variation rather than cancer-associated checkpoint loss. Collectively, these observations suggest that microtubule-depolymerizing agents have effects that are more complicated and more diverse than previously appreciated.

Acknowledgments

We thank Wilma Lingle for gifts of several HMEC isolates; Song Tao-Liu for collaborative work examining mitotic checkpoint proteins; Jeff Salisbury for use of his fluorescent microscope; Larry Karnitz, Tim Yen, Nita Mahille, Jann Sarkaria, Junjie Chen, and William C. Earnshaw for helpful discussions; and the anonymous reviewers for helpful suggestions. This work was supported in part by NIH grant R01 CA-69008 and predoctoral fellowships from the Mayo Foundation.


